89aee12bd5f1a3d3afe754dfe94a93d3 329182.pdf 7c8ee7e9fe40299d1467756a40454e52525790cc 329182.pdf 24f9ede03af0a8f461aede174519531687cdf81fc2d5430b6d6c19bfff26fe02 329182.pdf Title: Stage III NSCLC Treatment Patterns in Spain: A Population-Based Study of the GOECP-SEOR Subject: Objective: We aimed to provide real-world insights into the management of non-small cell lung cancer stage III (NSCLC-SIII) in Spain. Methods: The GOECP-SEOR group conducted an observational, retrospective, multicenter study in which data from patients diagnosed with NSCLC-SIII treated in Spanish radiotherapy departments (RTDs) were collected. Results: A total of 1505 NSCLC-SIII patients from 35 RTDs from 2018 to 2021 were recruited. A total of 871 patients (57.9%) received concurrent chemoradiotherapy (cCRT), and 390 patients (25.91%) received maintenance durvalumab. The immunotherapy (IT) was well tolerated, with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0–2 toxicity observed in 85% of the patients (295 patients). The median overall survival (OS) was 26 months (95% CI 9.4-Not Reached NR). There was a statistically significant difference when patients were stratified by IT, with a median OS of 40 months (95% CI 22.1-NR) in the IT maintenance cohort compared with 19.4 months (95% CI 7.1–58.1) in the non-IT cohort. Differences were also noted in progression-free survival (PFS), with a median PFS of 20.8 months (95% CI 9.6-NR) in the IT cohort versus 8.4 months (95% CI 3.1–25.1) in the non-IT cohort. These differences remained significant according to the multivariate model (OS: HR 0.45 [95% CI 0.36–0.56], p < 0.001; PFS: HR 0.5 [95% CI 0.42–0.59], p < 0.001). Conclusions: The management of NSCLC-SIII patients can vary, leading to differences in treatment outcomes. The treatment of lung cancer in NSCLC-SIII patients in RTDs across Spain aligns with international guidelines and expert recommendations. Keywords: non-small cell lung cancer stage III; concurrent chemoradiotherapy; immunotherapy; durvalumab; observational; population-based; real-world study Author: Paloma Sosa-Fajardo, Margarita Martín-Martín, Javier Luna-Tirado, José Luis López-Guerra, Elías Gomis-Sellés, Miriam López-Mata, Germán Valtueña-Peydró, Marina Santos-Rodríguez, Ana-María Álvarez-González, Guillermo Potdevin-Stein, Paula Martín-Barrientos, Andrea Kannemann, Nuria Farré-Bernadó, Elisabet González-Portillo, Aurea Manso-Lema, Marta Rodríguez-Roldán, María-Ángeles González-Ruiz, Amadeo Wals-Zurita, Nuria-Azahara Linares-Mesa, Sara Garduño-Sánchez, Patricia Barrionuevo-Castillo, Beatriz Moreno-Fuentes, Maximiliano Martos-Alcalde, Paula Simón-Silva, Mariana-Teresa Peña-Perea, Manuel-Luis Blanco-Villar, Victoria Vera-Barragán, Abrahams Ocanto-Martínez, María Mateos-Domínguez, Carmen Vallejo-Ocaña, Raúl Hernanz-Lucas, José-Enrique Castro-Gómez, Marina Peña-Huertas, Víctor Duque-Santana, José Zapatero-Ortuño, Celia García-Torres, Patricia Valencia-Nieto, Patricia Diezhandino-García, Clara Eito-Valdovinos, Alicia Olarte-García, Luis-Leonardo Guerrero-Gómez, Sofía Sánchez-García, Andrea Bobo-Jaureguizar, Amalia Sotoca-Ruiz, Beatriz Vázquez-Barreiro, Guillermo Cameselle-Gallego, Sonia Flamarique-Andueza, Mikel Rico-Oses, Marcos Guijarro-Verdu, Miguel Montijano-Linde, Laura Guzmán-Gómez, Ana-Belén Bezares-Alarcón, Cristina Cigarral-García, Paloma Moreno-Ceano, Javier Serrano-Andreu, Mauricio Murcia-Mejía, María Pagola-Divassón, Francesc Casas-Duran, Piedad Almendros-Blanco, Sara Pedraza-Fernández, José-Antonio González-Ferreira, Pino Alcántara and Felipe Couñago Creator: LaTeX with hyperref Producer: pdfTeX-1.40.25; modified using OpenPDF 1.4.2 CreationDate: Fri Nov 28 10:11:06 2025 CET ModDate: Fri Nov 28 10:17:19 2025 CET Custom Metadata: yes Metadata Stream: no Tagged: no UserProperties: no Suspects: no Form: none JavaScript: no Pages: 20 Encrypted: no Page size: 595.276 x 841.89 pts (A4) Page rot: 0 File size: 986220 bytes Optimized: no PDF version: 1.7 name type encoding emb sub uni object ID ------------------------------------ ----------------- ---------------- --- --- --- --------- VUSXBJ+URWPalladioL-Ital Type 1 Custom yes yes yes 149 0 FIGKFV+URWPalladioL-Bold Type 1 Custom yes yes yes 150 0 AVNOMV+URWPalladioL-Roma Type 1 Custom yes yes yes 151 0 JGMOZW+CMSY10 Type 1 Builtin yes yes yes 199 0 FAECIJ+URWPalladioL-BoldItal Type 1 Custom yes yes yes 217 0 BHIDLM+PalatinoLinotype TrueType WinAnsi yes yes no 242 0 BHIDLK+PalatinoLinotype,Bold TrueType WinAnsi yes yes no 243 0 BHIDLI+PalatinoLinotype,Italic TrueType WinAnsi yes yes no 290 0 Jhove (Rel. 1.28.0, 2023-05-18) Date: 2026-06-23 04:12:25 CEST RepresentationInformation: 329182.pdf ReportingModule: PDF-hul, Rel. 1.12.4 (2023-03-16) LastModified: 2026-06-22 12:56:21 CEST Size: 986220 Format: PDF Version: 1.7 Status: Well-Formed and valid SignatureMatches: PDF-hul MIMEtype: application/pdf PDFMetadata: Objects: 447 FreeObjects: 1 IncrementalUpdates: 0 DocumentCatalog: ViewerPreferences: HideToolbar: false HideMenubar: false HideWindowUI: false FitWindow: true CenterWindow: false DisplayDocTitle: false NonFullScreenPageMode: UseNone Direction: L2R ViewArea: CropBox ViewClip: CropBox PrintArea: CropBox PageClip: CropBox PageLayout: SinglePage PageMode: UseNone Outlines: Item: Title: Introduction Children: Item: Title: Background Item: Title: Problem Statement Item: Title: Materials and Methods Children: Item: Title: Design Item: Title: Selection of Patients Item: Title: Data Collection Item: Title: Ethics Committee Approval Item: Title: Statistical Analysis Item: Title: Results Children: Item: Title: Baseline Characteristics of Patients and Disease Item: Title: Treatment Characteristics Item: Title: Local Control Item: Title: Overall Survival Item: Title: Progression-Free Survival Item: Title: Toxicity Item: Title: Discussion Item: Title: Future Perspectives and Recommendations Item: Title: Study Limitations Item: Title: Conclusions Item: Title: References Info: Title: Stage III NSCLC Treatment Patterns in Spain: A Population-Based Study of the GOECP-SEOR Author: Paloma Sosa-Fajardo, Margarita Martín-Martín, Javier Luna-Tirado, José Luis López-Guerra, Elías Gomis-Sellés, Miriam López-Mata, Germán Valtueña-Peydró, Marina Santos-Rodríguez, Ana-María Álvarez-González, Guillermo Potdevin-Stein, Paula Martín-Barrientos, Andrea Kannemann, Nuria Farré-Bernadó, Elisabet González-Portillo, Aurea Manso-Lema, Marta Rodríguez-Roldán, María-Ángeles González-Ruiz, Amadeo Wals-Zurita, Nuria-Azahara Linares-Mesa, Sara Garduño-Sánchez, Patricia Barrionuevo-Castillo, Beatriz Moreno-Fuentes, Maximiliano Martos-Alcalde, Paula Simón-Silva, Mariana-Teresa Peña-Perea, Manuel-Luis Blanco-Villar, Victoria Vera-Barragán, Abrahams Ocanto-Martínez, María Mateos-Domínguez, Carmen Vallejo-Ocaña, Raúl Hernanz-Lucas, José-Enrique Castro-Gómez, Marina Peña-Huertas, Víctor Duque-Santana, José Zapatero-Ortuño, Celia García-Torres, Patricia Valencia-Nieto, Patricia Diezhandino-García, Clara Eito-Valdovinos, Alicia Olarte-García, Luis-Leonardo Guerrero-Gómez, Sofía Sánchez-García, Andrea Bobo-Jaureguizar, Amalia Sotoca-Ruiz, Beatriz Vázquez-Barreiro, Guillermo Cameselle-Gallego, Sonia Flamarique-Andueza, Mikel Rico-Oses, Marcos Guijarro-Verdu, Miguel Montijano-Linde, Laura Guzmán-Gómez, Ana-Belén Bezares-Alarcón, Cristina Cigarral-García, Paloma Moreno-Ceano, Javier Serrano-Andreu, Mauricio Murcia-Mejía, María Pagola-Divassón, Francesc Casas-Duran, Piedad Almendros-Blanco, Sara Pedraza-Fernández, José-Antonio González-Ferreira, Pino Alcántara and Felipe Couñago Subject: Objective: We aimed to provide real-world insights into the management of non-small cell lung cancer stage III (NSCLC-SIII) in Spain. Methods: The GOECP-SEOR group conducted an observational, retrospective, multicenter study in which data from patients diagnosed with NSCLC-SIII treated in Spanish radiotherapy departments (RTDs) were collected. Results: A total of 1505 NSCLC-SIII patients from 35 RTDs from 2018 to 2021 were recruited. A total of 871 patients (57.9%) received concurrent chemoradiotherapy (cCRT), and 390 patients (25.91%) received maintenance durvalumab. The immunotherapy (IT) was well tolerated, with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0–2 toxicity observed in 85% of the patients (295 patients). The median overall survival (OS) was 26 months (95% CI 9.4-Not Reached NR). There was a statistically significant difference when patients were stratified by IT, with a median OS of 40 months (95% CI 22.1-NR) in the IT maintenance cohort compared with 19.4 months (95% CI 7.1–58.1) in the non-IT cohort. Differences were also noted in progression-free survival (PFS), with a median PFS of 20.8 months (95% CI 9.6-NR) in the IT cohort versus 8.4 months (95% CI 3.1–25.1) in the non-IT cohort. These differences remained significant according to the multivariate model (OS: HR 0.45 [95% CI 0.36–0.56], p < 0.001; PFS: HR 0.5 [95% CI 0.42–0.59], p < 0.001). Conclusions: The management of NSCLC-SIII patients can vary, leading to differences in treatment outcomes. The treatment of lung cancer in NSCLC-SIII patients in RTDs across Spain aligns with international guidelines and expert recommendations. Keywords: non-small cell lung cancer stage III; concurrent chemoradiotherapy; immunotherapy; durvalumab; observational; population-based; real-world study Creator: LaTeX with hyperref Producer: pdfTeX-1.40.25; modified using OpenPDF 1.4.2 CreationDate: Fri Nov 28 10:11:06 CET 2025 ModDate: Fri Nov 28 10:17:19 CET 2025 ID: 0xd5f6733edf441277fa2cdbe19dc9403f, 0xaf0e290a7ca52c1055d8a758ca91e254 Filters: FilterPipeline: FlateDecode Fonts: Type1: Font: BaseFont: VUSXBJ+URWPalladioL-Ital FontSubset: true FirstChar: 45 LastChar: 121 FontDescriptor: FontName: VUSXBJ+URWPalladioL-Ital Flags: Symbolic FontBBox: -170, -305, 1010, 941 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: FIGKFV+URWPalladioL-Bold FontSubset: true FirstChar: 3 LastChar: 250 FontDescriptor: FontName: FIGKFV+URWPalladioL-Bold Flags: Symbolic FontBBox: -152, -301, 1000, 935 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: AVNOMV+URWPalladioL-Roma FontSubset: true FirstChar: 2 LastChar: 243 FontDescriptor: FontName: AVNOMV+URWPalladioL-Roma Flags: Symbolic FontBBox: -166, -283, 1021, 943 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Font: BaseFont: JGMOZW+CMSY10 FontSubset: true FirstChar: 6 LastChar: 21 FontDescriptor: FontName: JGMOZW+CMSY10 Flags: Symbolic FontBBox: -29, -960, 1116, 775 FontFile: true ToUnicode: true Font: BaseFont: FAECIJ+URWPalladioL-BoldItal FontSubset: true FirstChar: 78 LastChar: 112 FontDescriptor: FontName: FAECIJ+URWPalladioL-BoldItal Flags: Symbolic FontBBox: -170, -300, 1073, 935 FontFile: true EncodingDictionary: Differences: true ToUnicode: true Pages: Page: Sequence: 1 Annotations: Annotation: Subtype: Link Rect: 34, 177, 152, 186 Annotation: Subtype: Link Rect: 34, 167, 87, 174 Annotation: Subtype: Link Rect: 36, 75, 152, 84 Annotation: Subtype: Link Rect: 34, 63, 89, 72 Annotation: Subtype: Link Rect: 34, 773, 130, 809 Annotation: Subtype: Link Rect: 515, 773, 560, 809 Annotation: Subtype: Link Rect: 136, 664, 147, 677 Annotation: Subtype: Link Rect: 270, 664, 282, 677 Annotation: Subtype: Link Rect: 356, 650, 367, 663 Annotation: Subtype: Link Rect: 135, 622, 146, 636 Annotation: Subtype: Link Rect: 502, 622, 513, 636 Annotation: Subtype: Link Rect: 183, 608, 194, 622 Annotation: Subtype: Link Rect: 302, 608, 313, 622 Annotation: Subtype: Link Rect: 276, 581, 287, 594 Annotation: Subtype: Link Rect: 166, 566, 177, 580 Annotation: Subtype: Link Rect: 152, 538, 163, 552 Annotation: Subtype: Link Rect: 149, 525, 160, 538 Annotation: Subtype: Link Rect: 304, 511, 315, 524 Annotation: Subtype: Link Rect: 444, 511, 455, 524 Annotation: Subtype: Link Rect: 135, 497, 146, 510 Annotation: Subtype: Link Rect: 274, 497, 285, 510 Annotation: Subtype: Link Rect: 145, 469, 156, 482 Annotation: Subtype: Link Rect: 294, 469, 305, 482 Annotation: Subtype: Link Rect: 428, 469, 439, 482 Annotation: Subtype: Link Rect: 164, 441, 175, 455 Annotation: Subtype: Link Rect: 458, 441, 469, 455 Annotation: Subtype: Link Rect: 136, 427, 147, 441 Annotation: Subtype: Link Rect: 409, 27, 560, 37 Annotation: Subtype: Link Rect: 34, 391, 87, 410 Page: Sequence: 2 Page: Sequence: 3 Annotations: Annotation: Subtype: Link Rect: 493, 320, 500, 329 ActionDest: 101 Annotation: Subtype: Link Rect: 503, 320, 510, 329 ActionDest: 101 Annotation: Subtype: Link Rect: 513, 279, 520, 287 ActionDest: 101 Annotation: Subtype: Link Rect: 195, 237, 202, 246 ActionDest: 101 Annotation: Subtype: Link Rect: 205, 237, 217, 246 ActionDest: 190 Annotation: Subtype: Link Rect: 196, 209, 208, 218 ActionDest: 190 Annotation: Subtype: Link Rect: 211, 209, 222, 218 ActionDest: 190 Annotation: Subtype: Link Rect: 411, 97, 423, 106 ActionDest: 190 Page: Sequence: 4 Annotations: Annotation: Subtype: Link Rect: 518, 744, 530, 754 ActionDest: 190 Annotation: Subtype: Link Rect: 533, 745, 545, 754 ActionDest: 190 Annotation: Subtype: Link Rect: 295, 703, 307, 712 ActionDest: 190 Annotation: Subtype: Link Rect: 530, 605, 537, 614 ActionDest: 101 Annotation: Subtype: Link Rect: 198, 591, 209, 600 ActionDest: 190 Annotation: Subtype: Link Rect: 409, 563, 421, 572 ActionDest: 190 Page: Sequence: 5 Page: Sequence: 6 Annotations: Annotation: Subtype: Link Rect: 498, 709, 505, 721 ActionDest: 49 Page: Sequence: 7 Page: Sequence: 8 Annotations: Annotation: Subtype: Link Rect: 412, 446, 418, 458 ActionDest: 60 Annotation: Subtype: Link Rect: 471, 446, 478, 458 ActionDest: 65 Page: Sequence: 9 Page: Sequence: 10 Annotations: Annotation: Subtype: Link Rect: 194, 417, 201, 429 ActionDest: 65 Page: Sequence: 11 Annotations: Annotation: Subtype: Link Rect: 200, 576, 207, 588 ActionDest: 70 Annotation: Subtype: Link Rect: 369, 534, 376, 546 ActionDest: 231 Annotation: Subtype: Link Rect: 332, 409, 340, 421 ActionDest: 231 Annotation: Subtype: Link Rect: 324, 340, 331, 351 ActionDest: 231 Page: Sequence: 12 Page: Sequence: 13 Annotations: Annotation: Subtype: Link Rect: 432, 499, 438, 511 ActionDest: 75 Annotation: Subtype: Link Rect: 470, 457, 477, 469 ActionDest: 231 Annotation: Subtype: Link Rect: 534, 416, 541, 428 ActionDest: 79 Annotation: Subtype: Link Rect: 382, 374, 389, 386 ActionDest: 79 Page: Sequence: 14 Annotations: Annotation: Subtype: Link Rect: 202, 292, 209, 302 ActionDest: 79 Page: Sequence: 15 Annotations: Annotation: Subtype: Link Rect: 342, 602, 354, 611 ActionDest: 329 Annotation: Subtype: Link Rect: 516, 574, 527, 583 ActionDest: 329 Annotation: Subtype: Link Rect: 520, 560, 532, 569 ActionDest: 190 Annotation: Subtype: Link Rect: 532, 561, 544, 569 ActionDest: 190 Annotation: Subtype: Link Rect: 544, 561, 556, 569 ActionDest: 190 Annotation: Subtype: Link Rect: 247, 477, 259, 486 ActionDest: 329 Annotation: Subtype: Link Rect: 260, 477, 272, 486 ActionDest: 329 Annotation: Subtype: Link Rect: 369, 435, 381, 444 ActionDest: 329 Annotation: Subtype: Link Rect: 543, 393, 555, 402 ActionDest: 329 Annotation: Subtype: Link Rect: 233, 310, 245, 319 ActionDest: 329 Annotation: Subtype: Link Rect: 513, 198, 525, 207 ActionDest: 190 Annotation: Subtype: Link Rect: 526, 198, 538, 207 ActionDest: 190 Annotation: Subtype: Link Rect: 195, 157, 207, 166 ActionDest: 190 Annotation: Subtype: Link Rect: 441, 101, 452, 110 ActionDest: 329 Page: Sequence: 16 Annotations: Annotation: Subtype: Link Rect: 377, 730, 384, 740 ActionDest: 101 Annotation: Subtype: Link Rect: 530, 605, 542, 614 ActionDest: 329 Annotation: Subtype: Link Rect: 200, 354, 212, 364 ActionDest: 329 Annotation: Subtype: Link Rect: 308, 159, 320, 169 ActionDest: 329 Annotation: Subtype: Link Rect: 543, 160, 555, 169 ActionDest: 190 Annotation: Subtype: Link Rect: 388, 118, 400, 127 ActionDest: 329 Page: Sequence: 17 Annotations: Annotation: Subtype: Link Rect: 192, 508, 204, 517 ActionDest: 329 Page: Sequence: 18 Annotations: Annotation: Subtype: Link Rect: 393, 282, 431, 293 Annotation: Subtype: Link Rect: 437, 282, 473, 293 Annotation: Subtype: Link Rect: 59, 257, 96, 267 Annotation: Subtype: Link Rect: 102, 257, 138, 267 Annotation: Subtype: Link Rect: 282, 231, 319, 242 Annotation: Subtype: Link Rect: 325, 231, 361, 242 Annotation: Subtype: Link Rect: 95, 193, 132, 203 Annotation: Subtype: Link Rect: 217, 155, 254, 165 Annotation: Subtype: Link Rect: 299, 116, 337, 127 Annotation: Subtype: Link Rect: 200, 77, 238, 88 Page: Sequence: 19 Annotations: Annotation: Subtype: Link Rect: 205, 731, 242, 742 Annotation: Subtype: Link Rect: 278, 679, 315, 690 Annotation: Subtype: Link Rect: 59, 642, 96, 652 Annotation: Subtype: Link Rect: 95, 591, 133, 601 Annotation: Subtype: Link Rect: 104, 540, 142, 550 Annotation: Subtype: Link Rect: 520, 501, 557, 512 Annotation: Subtype: Link Rect: 364, 462, 401, 473 Annotation: Subtype: Link Rect: 158, 425, 195, 435 Annotation: Subtype: Link Rect: 201, 425, 237, 435 Annotation: Subtype: Link Rect: 520, 399, 557, 410 Annotation: Subtype: Link Rect: 519, 373, 557, 384 Annotation: Subtype: Link Rect: 59, 361, 95, 371 Annotation: Subtype: Link Rect: 298, 322, 336, 333 Annotation: Subtype: Link Rect: 59, 272, 96, 282 Annotation: Subtype: Link Rect: 102, 272, 138, 282 Annotation: Subtype: Link Rect: 374, 245, 412, 256 Annotation: Subtype: Link Rect: 405, 220, 442, 231 Annotation: Subtype: Link Rect: 185, 182, 223, 193 Annotation: Subtype: Link Rect: 229, 182, 265, 193 Annotation: Subtype: Link Rect: 461, 156, 498, 167 Annotation: Subtype: Link Rect: 300, 118, 338, 129 Annotation: Subtype: Link Rect: 113, 80, 150, 90 Page: Sequence: 20 Annotations: Annotation: Subtype: Link Rect: 475, 731, 513, 742 Annotation: Subtype: Link Rect: 95, 680, 132, 690 Annotation: Subtype: Link Rect: 56, 654, 520, 665 Annotation: Subtype: Link Rect: 519, 603, 557, 614 Annotation: Subtype: Link Rect: 59, 591, 95, 601 Annotation: Subtype: Link Rect: 274, 552, 311, 563 Annotation: Subtype: Link Rect: 59, 514, 96, 524 Annotation: Subtype: Link Rect: 102, 514, 138, 524 Annotation: Subtype: Link Rect: 351, 475, 389, 486 Annotation: Subtype: Link Rect: 395, 475, 431, 486 Annotation: Subtype: Link Rect: 256, 450, 293, 461 Annotation: Subtype: Link Rect: 300, 450, 336, 461 Annotation: Subtype: Link Rect: 447, 411, 485, 422 Annotation: Subtype: Link Rect: 491, 411, 527, 422 Annotation: Subtype: Link Rect: 185, 373, 222, 384 Checksum: d973af88 Type: CRC32 Checksum: 89aee12bd5f1a3d3afe754dfe94a93d3 Type: MD5 Checksum: 7c8ee7e9fe40299d1467756a40454e52525790cc Type: SHA-1 Checksum: 24f9ede03af0a8f461aede174519531687cdf81fc2d5430b6d6c19bfff26fe02 Type: SHA-256